UVA and MVA* analyses of mGPS and survival outcomes
| Variable | UVA | MVA* | |||||||
| OS | PFS | OS | PFS | ||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| Baseline mGPS | 2 (n=37) | 4.29 (2.24–8.24) | <0.001† | 1.90 (1.20–3.01) | 0.006† | 3.61 (1.78–7.31) | <0.001† | 1.87 (1.17–2.97) | 0.008† |
| 1 (n=62) | 2.78 (1.49–5.17) | 0.001† | 1.33 (0.88–2.01) | 0.183 | 1.82 (0.94–3.54) | 0.076 | 1.19 (0.77–1.85) | 0.435 | |
| 0 (n=57) | – | – | – | – | – | – | – | – | |
*The Cox proportional hazard model was fitted followed by backward variable elimination with a significance level of p<0.1. The covariables controlled for included age, sex, race, baseline Body Mass Index, sites of metastases, ECOG performance status, clear cell histology and prior lines of therapy.
†Statistical significance at alpha<0.05.
ECOG, Eastern Cooperative Oncology Group; mGPS, modified Glasgow Prognostic Score; MVA, multivariate analysis; OS, overall survival; PFS, progression-free survival; UVA, univariate analysis.